Affiliation:
1. Jacobi Medical Center
2. McFarland Clinic
3. University of Alabama at Birmingham
4. Montefiore Medical Center
5. Hackensack University Medical Center
Abstract
Abstract
Background
Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). Interstitial fibrosis/tubular atrophy (IFTA) on kidney biopsies strongly predicts progression to end-stage renal disease. However, factors associated with progression of IFTA are not known. The objective of this study was to evaluate the demographic, clinical, and histopathological factors at the time of index kidney biopsies that are associated with worsening IFTA on repeat biopsies.
Methods
Patients with LN Class I to V or mixed LN on index biopsies who underwent a clinically indicated repeat biopsy between 2004 and 2020 were identified. None-mild IFTA was defined as < 25% acreage of the interstitium affected by fibrosis and atrophy, and moderate-severe IFTA was defined as ≥ 25% of the interstitium affected. Patients with none-mild IFTA on index biopsies who progressed to moderate-severe IFTA on repeat biopsies were defined as progressors. Patients with none-mild IFTA on both biopsies were defined as non-progressors.
Results
Seventy-two patients who underwent clinically indicated repeat kidney biopsies were included, and 35 (49%) were identified as progressors. Compared to non-progressors, progressors had a higher proportion of proliferative LN (20 [57%] vs. 6 [17%], p = 0.002) and crescents (9 [26%] vs. 3 [8%], p = 0.045) on index biopsies. There was no difference regarding the time to repeat biopsy or the baseline characteristics, including eGFR, presence of hypertension and diabetes, urine protein to creatinine ratio, or the initial treatments.
Conclusions
Proliferative LN and the presence of crescents on index biopsies were associated with subsequent IFTA progression on repeat biopsies. This association indicates that glomerular damage is one of the major drivers of tubulointerstitial scarring in SLE. IFTA progression may, in turn, be the driving factor of poor treatment response and progression to chronic kidney disease.
Publisher
Research Square Platform LLC
Reference24 articles.
1. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis;Hahn B;Arthritis Care Res (Hoboken),2012
2. The classification of glomerulonephritis in systemic lupus erythematosus revisited;Weening JJ;Kidney Int,2004
3. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices;Bajema IM;Kidney Int,2018
4. Hsieh C, et al. Tubulointerstitial inflammation and scarring predict outcome in lupus nephritis. Volume 63. Arthritis care & research; 2011. p. 865. 6.
5. Leatherwood C, et al. Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. Seminars in arthritis and rheumatism. Elsevier; 2019.